There is growing evidence for a genetic overlap between some autoimmune conditions and certain psychiatric disorders, but the overlap is modest, heterogeneous, and disease-specific rather than universal. Large-scale analyses using genome-wide data have detected shared genetic signals and correlations that point to immune-related biology playing a role in mental health risk.
Evidence from population genetics and epidemiology
Using LD score regression across many genome-wide association studies, Brendan Bulik-Sullivan at the Broad Institute and colleagues published an atlas of genetic correlations showing that some autoimmune traits and psychiatric traits share modest but statistically significant genetic correlation. The Psychiatric Genomics Consortium led further cross-disorder analyses that have identified overlapping loci, particularly within immune-related regions such as the MHC/HLA region. Lars H. Benros at Statens Serum Institut and the University of Copenhagen provided complementary epidemiological evidence from Danish population registers showing elevated rates of psychiatric diagnoses after autoimmune disease and vice versa, indicating that genetic findings are reflected in real-world comorbidity patterns. Golam Khandaker at the University of Cambridge has reviewed mechanistic and clinical studies linking peripheral inflammation to mood and psychotic disorders, reinforcing the biological plausibility of shared pathways.
Mechanisms, causes, and consequences
Shared risk likely arises from pleiotropy—single genetic variants affecting both immune function and brain biology—and from convergent pathways such as cytokine signaling, microglial activation, and blood–brain barrier integrity. The MHC/HLA region is a recurrently implicated genomic area that influences immune recognition and also modulates neurodevelopmental processes. Environmental triggers like infections, stress, and smoking interact with genetic susceptibility so that genetic overlap increases risk only in particular contexts. Clinically, recognizing shared biology has consequences: it motivates trials of anti-inflammatory or immunomodulatory strategies for subsets of depression and psychosis and encourages integrated care where autoimmune and psychiatric symptoms co-occur.
Nuance is important: genetic correlations do not imply that most people with autoimmune disease will develop psychiatric illness or vice versa. Geographical, cultural, and healthcare factors—differences in infection exposure, diagnostic practices, and access to specialty care—shape observed comorbidity patterns across populations. Ongoing work by international consortia integrating genetics, immunology, and longitudinal clinical data aims to clarify which patients might benefit from immune-targeted interventions.